NASDAQ$ROIV

Roivant Sciences Ltd · Q3 2026 earnings

Q3 2026 earnings · · Before market open · Investor relations

Briefing

Roivant Sciences reported Q3 2026, net loss of $120M.

For Q3 2026, Roivant Sciences reported a net loss of $120M. Management discusses operating trends, capital allocation, and outlook in the earnings release or periodic filing.

  • Net loss $120M.
  • Roivant Sciences highlights liquidity, costs, and 2026 priorities.
  • Roivant Sciences highlights liquidity, costs, and 2026 priorities.

Headline financials

Total Revenue

$2M

No prior period
EPS (adj)

-$0.24

No prior period
G&A expenses

$175M

No prior period
R&D expenses

$165M

No prior period
Capital Expenditures

-$6.95M

No prior period
Net Income

-$266M

No prior period
Operating Income

-$339M

No prior period

Revenue & EPS history

Roivant Sciences · Revenue · Quarterly

$2M

Q3 2026
Beat estimate in 7 of 14 quarters(50%)
ActualEstimate

Forward guidance

The filing outlines Roivant Sciences's outlook, including operating priorities, capital allocation, and key risks, with specific numeric guidance where management provided it.

Tailwinds

  • Roivant Sciences cites execution on growth initiatives and balance-sheet flexibility.
  • Management emphasizes capital returns and operational priorities in the filing.

Headwinds

  • Pre-revenue or development-stage operations depend on financing and pipeline milestones.
  • GAAP profitability remained under pressure in Q3 2026.
  • Macro, pricing, and competitive pressure may affect margins.
  • One-time items and segment mix can affect quarter-to-quarter comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2026

Historical avgQ3 2026

+3.3%

Avg return

Earnings day

+1.0%

Avg return

5 days after

+1.0%

Avg return

30 days after

60%

12 / 20 earnings

Positive

+22.1%

Q3 2026

Best reaction

-5.5%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+14.9%+6.2%+11.4%
Q3 2026+22.1%+26.8%+36.1%
Q2 2026+2.6%-1.6%-1.8%
Q1 2026-2.8%+3.1%+19.8%
Q4 2025+6.4%+5.9%+7.3%
Q4 2024-3.4%+0.0%-1.5%
Q3 2024+4.1%+6.6%-5.9%
Q2 2024+5.6%+1.8%+22.7%
Q1 2024-5.2%-6.1%-3.5%
Q4 2023+9.4%+7.8%+28.8%
Q3 2023+9.7%+8.2%+7.8%
Q2 2023+7.4%-3.1%+39.9%
Q1 2023-5.5%-15.3%-15.8%
Q4 2022-4.1%-5.6%-11.8%
Q3 2021+5.1%-3.2%-25.4%
Q3 2022+5.4%-3.2%-25.4%
Q2 2022-2.4%-4.8%+6.8%
Q2 2021-3.8%-4.8%+6.8%
Q1 2021+0.1%+0.7%-38.7%
Q1 2022+0.0%+0.7%-38.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro